DIA to Shine Light on Newly Released PCAST Report “Reinventing the R&D Business Model: Heeding the President’s PCAST Report on Innovation” to Be Hosted by the Tufts Center for the Study of Drug Development DIA 2013 Business Wire HORSHAM, Pa. -- April 17, 2013 A consummate group of moderators and panelists will participate in an executive session at DIA’s 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science. The session, to be held on June 25 in Boston, will be hosted by the Tufts Center for the Study of Drug Development (CSDD) and focus on a report released in January by the President’s Council of Advisors on Science and Technology (PCAST). Included in the panel will be Bernard Munos, founder of InnoThink Center for Research in Biomedical Innovation, who was recently noted in FierceBiotech as one of the 25 most influential people in biopharma, and Dalvir Gill, CEO of TransCelerate Biopharma Inc. With the landscape for biopharmaceuticals rapidly changing, this senior-level session will examine how companies across the pharmaceutical sector are transforming their R&D business models to meet current and future market demands. Along with R&D, the panel will address preclinical, clinical, regulatory, operations, portfolio management and marketing issues—all aspects of business development. Susan Cantrell, director of DIA North America, said, “We are truly honored to have this panel, whose members bring unparalleled experience, expertise and thought leadership. With the insight of these esteemed panelists, we are certain this interactive session will provide invaluable information that will help companies to move their businesses forward. Their views and discussion of the PCAST report come at an exciting time as the country seeks to lead the world in health care innovation.” The moderators and panelists include: *Kenneth I. Kaitin, Ph.D. Professor and Director, CSDD Tufts University School of Medicine *Kenneth A. Getz, MBA Director of Sponsored Research, Tufts CSDD; Chairman, Center for Information and Study on Clinical Research Participation Tufts University DIA Chairman, 2011 *Bernard Munos, MBA Founder InnoThink Center for Research in Biomedical Innovation *Tomasz Sablinski, M.D. Founder and CEO Transparency Life Sciences *Robert J. Franco, Ph.D. Principal PricewaterhouseCoopers LLP *Andy Lee, M.D. Senior Vice President, Global Clinical Operations Genzyme *Dalvir Gill, Ph.D. CEO TransCelerate Biopharma Inc. Visit www.diahome.org/DIA2013 to learn more about DIA’s 2013 49th Annual Meeting. To schedule an interview with one of the panelists or to request a press credential, please contact Eric Rosen at email@example.com or at 215.290.9153. ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health-care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products,technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C. and Latin America. Visit our website at www.diahome.org and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest. Contact: DIA Eric Rosen, 215-290-9153 firstname.lastname@example.org
DIA to Shine Light on Newly Released PCAST Report
Press spacebar to pause and continue. Press esc to stop.